Fig. 3: Swimmer’s plot and PFS and OS estimates by study arm. | Nature Medicine

Fig. 3: Swimmer’s plot and PFS and OS estimates by study arm.

From: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Fig. 3

a, Swimmer’s plot of the study cohort stratified by treatment arm. PFS is presented alongside histology, surgery completion status, RECIST response and ctDNA status at C3D1 and pre-surgery for the 30 enrolled patients. Liquid biopsies during neoadjuvant treatment are indicated for relevant timepoints (C1D1 (D−42), C2D1 (D−28), C3D1 (D−14) and pre-surgery (D−3)), as are surgery, progression or recurrence and death. A total of seven patients did not undergo complete surgical resection. Of 28 patients evaluated for RECIST at baseline and pre-surgery, two had non-evaluable disease, 13 had SD, two had PR and 11 experienced PD. Patients in Arm A (n = 16) had a median PFS of 9.6 months (95% CI: 2.5–27.7) (b) and a median OS of 19.3 months (95% CI: 14.9–34.7) (c). Patients in Arm B (n = 14) had a median PFS of 19.8 months (95% CI: 7.1–NR) (d) and a median OS of 28.6 months (95% CI: 20.4–NR) (e). The median follow-up times for Arms A and B were 43.2 months and 24.1 months, respectively. D, day; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; UD, undetectable.

Back to article page